Dr. Reddy’s Laboratories Ltd ADR (RDY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $12.29B
Last updated: Nov 17, 2026 at 11:05 AM ET
Dr. Reddy’s Laboratories Ltd ADR (RDY) Financials: Revenue, Profit and Cash Flow
Dr. Reddy’s Laboratories Ltd ADR reported revenue of INR 353.47B for the fiscal year ended Mar 31, 2026, up 8.6% from the year before. That year, net income was INR 45.09B with a net margin of 12.8%, operating cash flow was INR 56.65B and free cash flow was INR 32.10B. The quarter ended Sep 30, 2026 had revenue of INR 86.59B and net income of INR 9.24B.
Revenue and Margins
The operating margin was 13.8% in the fiscal year ended Mar 2026. Over the 9 years to Mar 2026, revenue grew from INR 140.81B, a compound annual rate of 10.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | 353.47B | +8.6% | 52.8% | 13.8% | 12.8% |
| Mar 2025 | 325.54B | +16.6% | 58.5% | 22.1% | 17.4% |
| Mar 2024 | 279.16B | +13.5% | 58.6% | 24.3% | 19.9% |
| Mar 2023 | 245.88B | +14.7% | 56.7% | 23.2% | 18.3% |
| Mar 2022 | 214.39B | +8288.8% | 53.1% | 13.7% | 11.0% |
| Mar 2021 | 2.56B | -98.5% | 50.8% | 16.9% | 9.1% |
| Mar 2020 | 174.60B | +13.5% | 53.8% | 9.2% | 11.2% |
| Mar 2019 | 153.85B | +8.3% | 54.2% | 13.6% | 12.2% |
| Mar 2018 | 142.03B | +0.9% | 53.7% | 8.4% | 6.9% |
| Mar 2017 | 140.81B | N/A | 55.6% | 9.6% | 8.5% |
Income Statement
In the fiscal year ended Mar 2026, net income fell 20.3% from the year before. In the quarter ended Sep 2026, net income fell 35.7% from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 353.47B | 325.54B | 279.16B | 245.88B | 214.39B | 2.56B | 174.60B | 153.85B | 142.03B | 140.81B |
| Cost of revenue | 166.95B | 135.11B | 115.56B | 106.54B | 100.55B | 1.26B | 80.59B | 70.42B | 65.72B | 62.45B |
| Gross profit | 186.52B | 190.43B | 163.61B | 139.34B | 113.84B | 1.30B | 94.01B | 83.43B | 76.30B | 78.36B |
| Research and development | 25.31B | 27.38B | 22.87B | 19.38B | 17.48B | 208.37M | 15.41B | 15.61B | 18.27B | 19.55B |
| Operating income | 48.87B | 71.84B | 67.73B | 57.14B | 29.48B | 431.44M | 15.99B | 20.89B | 11.92B | 13.50B |
| Net income | 45.09B | 56.54B | 55.68B | 45.07B | 23.57B | 232.21M | 19.50B | 18.80B | 9.81B | 12.04B |
| EBITDA | 83.29B | 96.67B | 88.42B | 74.43B | 45.08B | 13.16B | 41.78B | 35.52B | 23.63B | 24.77B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86.59B | 81.18B | 76.33B | 87.27B | 88.05B | 85.45B | 85.06B | 83.59B | 80.16B | 76.73B | 70.83B | 72.15B |
| Gross profit | 45.14B | 37.76B | 34.22B | 46.81B | 48.14B | 48.63B | 47.26B | 49.05B | 47.77B | 46.34B | 41.48B | 42.20B |
| Operating income | 11.88B | 2.97B | 473.25M | 14.24B | 17.51B | 17.48B | 17.65B | 18.72B | 17.55B | 17.93B | 14.96B | 17.27B |
| Net income | 9.24B | 4.46B | 2.24B | 12.10B | 14.37B | 14.18B | 15.94B | 14.13B | 12.55B | 13.92B | 13.07B | 13.79B |
Balance Sheet
As of Mar 2026, total debt of INR 76.05B exceeded cash and equivalents by 60.99B.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 567.88B | 492.99B | 387.52B | 321.85B | 292.83B | 3.63B | 3.07B | 225.43B | 225.60B | 219.82B |
| Current assets | 296.00B | 250.11B | 248.05B | 204.25B | 181.86B | 2.03B | 1.72B | 114.50B | 109.64B | 100.38B |
| Cash and equivalents | 15.06B | 14.65B | 7.11B | 5.78B | 14.85B | 202.82M | 27.14M | 2.23B | 2.64B | 18.14B |
| Total liabilities | 194.95B | 155.82B | 106.97B | 90.86B | 102.30B | 1.26B | 1.02B | 85.23B | 99.14B | 95.78B |
| Short-term debt | 63.85B | 38.90B | 14.03B | 12.19B | 28.10B | 328.38M | 274.92M | 16.38B | 25.63B | 43.74B |
| Long-term debt | 12.20B | 3.80B | 3.80B | 0 | 5.75B | 6.30B | 0 | 21.45B | 24.46B | 4.85B |
| Shareholder equity | 369.60B | 333.39B | 280.55B | 230.99B | 190.53B | 2.37B | 2.05B | 140.20B | 126.46B | 124.04B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 577.00B | 575.30B | 567.88B | 562.90B | 542.00B | 519.54B | 492.99B | 481.06B | 465.95B | 415.30B | 387.52B | 372.84B |
| Total liabilities | 185.92B | 188.57B | 194.95B | 187.14B | 179.92B | 165.78B | 155.82B | 159.49B | 156.67B | 120.67B | 106.97B | 104.99B |
| Cash and equivalents | 13.35B | 11.20B | 15.06B | 18.66B | 9.91B | 9.00B | 14.65B | 12.29B | 11.33B | 4.91B | 7.11B | 7.34B |
| Shareholder equity | 387.87B | 383.43B | 369.60B | 372.37B | 358.49B | 350.06B | 333.39B | 317.72B | 305.34B | 294.63B | 280.55B | 267.85B |
Cash Flow
In the fiscal year ended Mar 2026, free cash flow was 56.7% of operating cash flow. Dividends came to 21.8% of it.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 56.65B | 46.43B | 45.43B | 58.87B | 28.11B | 35.70B | 29.84B | 28.70B | 18.03B | 21.51B |
| Capital expenditures | 24.54B | 34.40B | 27.43B | 18.86B | 19.05B | 12.56B | 6.12B | 7.49B | 11.04B | 40.98B |
| Free cash flow | 32.10B | 12.03B | 18.00B | 40.01B | 9.06B | 23.14B | 23.73B | 21.21B | 6.99B | -19.47B |
| Dividends paid | 7.01B | 6.66B | 6.65B | 4.98B | 4.15B | 4.15B | 3.92B | 4.00B | 3.99B | 3.39B |
| Investing cash flow | -70.53B | -58.08B | -40.28B | -41.37B | -26.39B | -22.66B | -4.92B | -7.73B | -14.88B | -18.47B |
| Financing cash flow | 13.40B | 18.91B | -3.76B | -26.86B | -2.42B | -298.00M | -25.16B | -21.33B | -4.44B | -3.69B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 4.69B | -927.00M | 15.44B | 10.91B | 15.57B | 14.63B | 22.00B | 6.62B | 9.32B | 8.50B | 136.19M | 4.74B |
| Capital expenditures | 2.39B | 3.70B | 4.69B | 7.32B | 10.13B | 10.15B | 11.25B | 8.82B | 7.91B | 6.42B | 63.29M | 5.04B |
| Free cash flow | 2.31B | -4.63B | 10.75B | 3.59B | 5.44B | 4.48B | 10.75B | -2.20B | 1.41B | 2.07B | 72.90M | -305.00M |
Frequently Asked Questions About RDY
What is Dr. Reddy’s Laboratories Ltd ADR's annual revenue?
Dr. Reddy’s Laboratories Ltd ADR reported revenue of INR 353.47B for the fiscal year ended Mar 31, 2026.
How fast is Dr. Reddy’s Laboratories Ltd ADR's revenue growing?
Revenue was up 8.6% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 12.9%.
Is Dr. Reddy’s Laboratories Ltd ADR profitable?
Yes. Dr. Reddy’s Laboratories Ltd ADR reported net income of INR 45.09B for the fiscal year ended Mar 31, 2026, with a net margin of 12.8%.
How much free cash flow does RDY generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of INR 56.65B minus capital expenditures of INR 24.54B produced free cash flow of INR 32.10B.
How much debt does Dr. Reddy’s Laboratories Ltd ADR have?
The balance sheet dated Mar 31, 2026 reported long-term debt of INR 12.20B, short-term debt of INR 63.85B and cash and equivalents of INR 15.06B.
RDY pages: Overview, Dividends, Financials, Valuation, Competitors